USP Comment Letter: Submitted to FDA ‘Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research; Guidance for Industry (2019)

Submitted on April 15, 2019 - USP Comment Letter to FDA on the Food and Drug Administration’s final guidance, “Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research - Guidance for Industry. Docket No. FDA-2017-D-6535.